While there may be some resistance to the conduction of clinical trials of pharmacological interventions in these clinical populations, the mechanistic profile of GLP-1RAs clearly suggests that these medications may play a role in the treatment of certain specific eating disorders, such as BED
BPC-157: 250-500 mcg once or twice daily for 6-8 week cycles Cryotherapy: 2-3 sessions per week (whole-body or local application) Schedule cryotherapy on high-activity or high-pain days Take 4-8 weeks off between BPC-157 cycles Approach for acute worsening of chronic conditions
Patients may experience variability at a particular pharmacy location regardless of whether a drug is in shortage
For genuine deficiency, low energy, or a faster absorption route than oral supplements
As research progresses, regulated pharmaceutical development may eventually offer validated pathways for NNMT inhibitors
Both assays were analyzed in duplicate using a TECAN Infinite M200 plate reader (Tecan Infinite 200, Tecan Group Ltd., Mnnedorf, Switzerland)